Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 9/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645365 | 0.88 | SIRT6 (0.67) | SIRT6BACE1ACACB | |
| SCHEMBL10328670 | 0.84 | SIRT6 (0.47) | SIRT6BACE1HCAR2KDM4EMAPK1 | |
| SCHEMBL1934141 | 0.83 | TSHR (0.45) | SIRT6BACE1KDM4EL3MBTL1 | |
| SCHEMBL14903882 | 0.83 | BACE1 (0.45) | SIRT6BACE1KDM4EL3MBTL1MAPT | |
| SCHEMBL12557562 | 0.82 | SIRT6 (0.42) | SIRT6BACE1ACACBNAMPT | |
| SCHEMBL2108443 | 0.81 | SIRT6 (0.43) | SIRT6BACE1HCAR2KDM4EMAPK1 | |
| SCHEMBL991588 | 0.80 | MAPT (0.56) | SIRT6HCAR2KDM4EMAPK1L3MBTL1 | |
| SCHEMBL7941192 | 0.80 | SIRT6 (0.44) | SIRT6BACE1HCAR2KDM4EMAPK1 | |
| SCHEMBL6819314 | 0.80 | TSHR (0.47) | SIRT6KDM4EL3MBTL1MAPT | |
| SCHEMBL10329868 | 0.80 | RARB (0.49) | SIRT6BACE1KDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| EP-3233834-B1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-13 | — | — | EP | disclosed |
| US-10106524-B2 | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20170362198-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | US | disclosed |
| EP-3233834-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2017-10-25 | — | — | EP | disclosed |
| EP-3010925-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-3010925-B1 | BACE INHIBITORS | LILLY CO ELI (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| WO-2010038686-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| EP-1572670-B1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7132425-B2 | 5-substituted-six-membered heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | CHEN SHAOQING (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093999-A1 | NOVEL FUSED AMINODIHYDROTHIAZINE DERIVATIVE | BACE1, BACE2, APP | SIRT6 2728/4885BACE1 1/4885HCAR2 1955/4885 |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | SIRT6 1476/4885BACE1 2/4885HCAR2 1261/4885 |
| US-20170362198-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE AND 3,4-DIHYDRO-2H-PYRROL-5-AMINE COMPOUND INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, APP | SIRT6 2406/4885BACE1 1/4885HCAR2 3400/4885 |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | GCK, GCKR, GALK1 | SIRT6 185/4885BACE1 2029/4885HCAR2 2591/4885 |
| US-10106524-B2 | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase | BACE1, BACE2, APP | SIRT6 2406/4885BACE1 1/4885HCAR2 3400/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | SIRT6 1402/4885BACE1 69/4885HCAR2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.